Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke
V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw
LM; Swedish BioFINDER study group; Alzheimer’s Disease Neuroimaging Initiative.
CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict
clinical progression: A study of fully automated immunoassays in BioFINDER and
ADNI cohorts. Alzheimers Dement. 2018 Mar 1. pii: S1552-5260(18)30029-3.
INTRODUCTION:
We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort.
METHODS:
Cutoffs for Elecsys amyloid-β1-42 (Aβ), total tau/Aβ(1-42), and phosphorylated tau/Aβ(1-42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18F]florbetapir PET in Alzheimer’s DiseaseNeuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied.
RESULTS:
CSF total tau/Aβ(1-42) and phosphorylated tau/Aβ(1-42) ratios were highly concordant with PET classification in BioFINDER(overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer’s Disease Neuroimaging Initiative (overall percent agreement: 89%-90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read-based outcomes.
DISCUSSION:
Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer’s disease diagnosis.